Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT

Evaluate if Y90 Ibritumomab Tiuxetan Radioimmunotherapy in addition to standard high dose chemotherapy followed by autologous stem cell transplant could improve prognosis in patients affected by relapsed/refractory aggressive non Hodgkin lymphoma

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Refractory B-Cell Non-Hodgkin Lymphoma Disease Attributes Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoma, B-Cell Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Pathologic Processes Pathological Conditions, Signs and Symptoms Recurrence Recurrent B-Cell Non-Hodgkin Lymphoma

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

High Risk Relapsed/refractory aggressive non-hodgkin lymphoma defined as:
Progressive disease
Early relapse (within 12 months from response)
Recurrent relapse
Treated with salvage chemotherapy followed by Y90 Ibritumomab Tiuxetan plus high-dose chemotherapy and Autologous stem cell transplant
Age > 18 years
Previous treatment with Rituximab
Written informed consent

Exclusion criteria

Patient with no complete data available for collection

Treatment and study plan

Primary outcomes

Overall Survival

Time frame: Date of last follow-up for at least 18 months (up to 78 months)

Time to last follow-up or death
Progression Free Survival

Time frame: From first response to last follow-up for at least 18 month (up to 78 months)

Time from last response to nearest relapse or follow-up

Sponsors and collaborators

Lead sponsor

A.O.U. Città della Salute e della Scienza

Other

Registry information

Official study title

Retrospective Collection of Data on Patient With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Y90 Ibritumomab Tiuxetan Radioimmunotherapy Plus High-Dose Chemotherapy and Autologous Stem Cell Transplant

Important dates

Study start: 2014
Primary completion: 2015
Study completion: 2015
First posted: Dec 14, 2016
Registry last updated: Dec 14, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed